Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cerovive; CPI 22; Disufenton sodium; NXY 059; NXY 059G

Latest Information Update: 16 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Renovis
  • Class Anti-ischaemics; Antineoplastics; Benzenesulfonates; Neuroprotectants; Nitrogen oxides; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 01 Nov 2006 Results from the phase III clinical trial SAINT II in patients with acute ischaemic stroke have been added to the adverse events and Neurological disorders therapeutic trials sections ,
  • 26 Oct 2006 Discontinued - Phase-III for Stroke in Asia, Australia, Canada, Europe, New Zealand, South Africa, South America, Sweden, United Kingdom, USA and Japan (IV-infusion)
  • 02 Aug 2006 Renovis has completed enrolment in the SAINT II trial for acute ischaemic stroke
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top